Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents.

ABSTRACT:

Background

Chemical agents such as alkylating agents (AAs) that are commonly used for the treatment of cancer cause great damage to the ovaries, thereby significantly increasing the risk of premature ovarian insufficiency (POI). However, the exact molecules underlying AA-induced POI remain largely obscure. Upregulation of the p16 gene may contribute to the progression of POI. As yet, no in vivo data from p16-deficient (KO) mice are available to demonstrate a critical role of p16 in POI. In the present study, we employed p16 KO mice to investigate whether loss of p16 could protect against POI caused by AAs.

Methods

WT mice and their p16 KO littermates received a single dose of BUL + CTX to establish an AA-induced POI mouse model. One month later, oestrous cycles were monitore

SUBMITTER: Liu F 

PROVIDER: S-EPMC9993597 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature